It has been one of the most eventful single days in recent pharmaceutical news. Novo Nordisk launched a rebrand, announced an AI drug discovery collaboration with Anthropic, and struck a $1.4 billion macrocycle partnership — all within 72 hours. Bayer received its third FDA indication for KERENDIA, the first new CKD treatment for Type 1 diabetes in 30 years. GSK made its second Chimagen acquisition. And Sanofi offloaded 20 mature medicines to Cheplapharm in the largest portfolio simplification move it has made to date. Here is a guide to every major story.

Novo's Rebrand and "The Novo Way"

What did Novo Nordisk actually change?

Novo Nordisk rebranded as "Novo" for day-to-day use, paired with the tagline "Lasting Health Starts Now" and a new cultural framework called "The Novo Way." The legal entity name — Novo Nordisk A/S — remains unchanged. The Apis bull logo is retained but modernized. The rebrand is designed to give the company a more consistent global identity that reflects how people engage with health today, positioning Novo's science as something relevant to everyday life rather than reserved for clinical settings.

Who is driving this change and why now?

Mike Doustdar, who became president and CEO earlier this year, is making this rebrand his first major public strategic statement. He took over a company navigating intensifying GLP-1 competition, a significant share price correction, and a board shake-up initiated by the Novo Nordisk Foundation. His message is that the unmet need in obesity and diabetes remains vast, that people's expectations of healthcare are changing, and that Novo's brand and culture need to evolve to match that reality.

What is "The Novo Way?”

The Novo Way is a four-principle cultural framework built around customer obsession, competitiveness, clarity, and care and integrity. Customer obsession commits the company to innovating with consumers and patients at the center. Competitiveness calls for raising performance to create greater value for stakeholders. Clarity is about creating focus and speed through clear priorities and decisive action. Care and integrity commits Novo to its people and to never compromising on patient safety and ethics.

What comes next?

Novo is providing a detailed overview of its updated corporate strategy at its Capital Markets Day on September 21 in London. That event will reveal the financial targets and pipeline commitments that back up the brand — and will be the moment where investors evaluate whether the rebrand represents a genuine strategic pivot or primarily a communications exercise.

Novo and Anthropic's AI Drug Discovery Collaboration

What did Novo and Anthropic announce?

Novo and Anthropic announced a collaboration to advance drug discovery using Claude Science and Anthropic's frontier AI models. The companies will jointly address key drug discovery challenges, develop targeted solutions for specific scientific workflows to support biological reasoning, and work to accelerate the discovery and development of new medicines. Novo will also use Anthropic's models to strengthen AI-driven software development across the company.

What is Claude Science?

Claude Science is Anthropic's AI system designed specifically for scientific reasoning — built to handle the kind of complex biological and chemical reasoning that underlies drug discovery, rather than general-purpose language tasks. The collaboration with Novo will test Claude Science on specific workflows in R&D and on scientific problems where the joint capabilities of both organizations are expected to have the greatest impact.

Why is this deal strategically significant for Novo?

Doustdar explicitly frames the collaboration as evidence of Novo's ambition to become "the world's most AI-driven healthcare company." The Anthropic partnership sits alongside Novo's existing AI collaboration with Amazon Web Services — announced earlier this year — which focuses on data infrastructure and model training. Together the two partnerships reveal that Novo is building a multi-partner AI ecosystem rather than betting on a single platform, with AWS handling data infrastructure and Anthropic handling biological reasoning and agentic software engineering.

What does Dario Amodei's "century of breakthroughs in a decade" claim actually mean?

Amodei's statement that AI brings "the potential to compress a century's worth of biological and medical breakthroughs into a decade" is a bold claim about what frontier AI models can do when applied to scientific reasoning at scale. The specific mechanism is the ability to generate and evaluate scientific hypotheses faster than any human research team can, to identify patterns across biological datasets too large and complex for human analysis, and to accelerate the iterative cycles of hypothesis, experiment, and interpretation that define drug discovery. Whether that potential translates into approved medicines will be measured over the next decade of Novo's R&D output.

Novo and Orbis Medicines' $1.4 Billion Macrocycle Partnership

What did Novo and Orbis announce?

Novo entered a strategic collaboration and license agreement with Orbis Medicines to discover and develop next-generation oral macrocycle therapeutics for cardiometabolic diseases. Orbis is eligible to receive more than $1.4 billion in upfront and potential development and commercial milestone payments, plus tiered royalties. Novo is also making a strategic equity investment in Orbis.

What is the nGen platform and why is it valuable?

Orbis's proprietary nGen platform integrates generative AI with high-throughput synthesis capabilities — what the company calls a lab-in-the-loop approach — to design macrocycles with good drug-like properties. Macrocycles are a class of molecules large enough to address biological targets that conventional small molecules cannot reach, but they have historically been difficult to make orally bioavailable. The nGen platform is designed to overcome that limitation by continuously learning from one of the industry's largest experimental macrocycle datasets, generated in real time through automated chemistry and screening. The ambition is to produce oral medicines capable of replacing injectable therapies for cardiometabolic diseases.

How does this deal connect to Novo's broader strategy?

Oral delivery is the defining competitive question in the GLP-1 and cardiometabolic market right now. Novo's orally available semaglutide has already demonstrated that oral delivery is achievable but still less efficacious than injectable forms. An AI-driven macrocycle platform that could generate first-in-class oral medicines for high-value cardiometabolic targets not addressable by existing small molecules would represent a meaningful scientific advance — and a significant commercial one, given what the market has already demonstrated about patient preference for oral versus injectable therapies.

Bayer's KERENDIA Approval for Type 1 Diabetes CKD

What was approved and why does it matter?

FDA approved KERENDIA (finerenone) as the first new treatment in 30 years for adults with chronic kidney disease associated with Type 1 diabetes. Today's approval marks KERENDIA's third FDA-approved indication, alongside its existing approvals for CKD with Type 2 diabetes and heart failure with preserved ejection fraction.

Approximately 20 to 30 percent of people with T1D develop CKD over the course of their lives — a population that has had access to standard-of-care treatments including ACE inhibitors, ARBs, and SGLT2 inhibitors, but no approved therapy directly targeting the mineralocorticoid receptor pathway that finerenone addresses. The 30-year gap reflects how difficult it has been to design a safe and effective nonsteroidal MRA for this population.

What was the evidence base?

The approval was based on the FINE-ONE trial, which showed a 28% reduction in urine albumin-to-creatinine ratio at month 6 compared to placebo in adults with CKD and T1D. UACR is a validated marker of kidney damage progression and is accepted by the FDA as a clinically meaningful endpoint in this population.

What does this mean for Bayer commercially?

KERENDIA grew 67.1% in Q2 2025 to approximately $200 million, making it one of Bayer's two primary commercial growth engines alongside Nubeqa during the company's ongoing $2.3 billion restructuring. A third indication that expands the eligible patient population could meaningfully accelerate that trajectory at a critical moment for the company's financial recovery.

GSK's Chimagen Trispecific T-Cell Engager Acquisition

What did GSK acquire?

GSK agreed to acquire a trispecific T-cell engager for multiple myeloma from Chimagen Biosciences for up to $750 million. This is GSK's second transaction with Chimagen — following an earlier agreement for CMG1A46, a dual CD19/CD20 T-cell engager. The new asset targets two tumor-associated antigens simultaneously using a trispecific antibody design, with Phase 1 planned for 2027.

What makes a trispecific approach distinctive?

By targeting two tumor-associated antigens alongside CD3 for T-cell recruitment, the Chimagen trispecific is designed to provide broader coverage across tumor cell populations and to offer a differentiated therapeutic option for patients who have already received prior bispecific TCE therapy. The design also aims to address the tolerability challenges that have been associated with existing T-cell engagers — a clinically meaningful goal in a patient population that often has limited treatment options and a high symptom burden.

Sanofi and Cheplapharm's Mature Medicine Partnership

What did Sanofi and Cheplapharm announce?

Sanofi announced a strategic partnership in which it will transfer 20 mature medicines and three manufacturing sites to Cheplapharm, the European specialist in mature pharmaceutical products. In exchange, Sanofi will receive a 26.4% equity stake in Cheplapharm. The portfolio includes Lovenox/Clexane (enoxaparin), one of the world's most widely prescribed anticoagulants.

Why is Sanofi doing this?

The transaction is the latest and largest step in Sanofi's multi-year portfolio simplification strategy. The company's CDO Emmanuel Frenehard has described the underlying philosophy explicitly: "You have to make choices. You have to concentrate your investment. You have to place big bets and not try to do a little bit of everything." Mature medicines and innovative medicines have different operational requirements — different manufacturing, regulatory, and commercial needs — and Cheplapharm, as a specialist in that category, is better positioned to maximize their value than a large pharma company simultaneously managing a late-stage innovation pipeline.

What is Sanofi doing with the resources being freed?

Sanofi is redirecting capital toward its innovation pipeline, including the recent $9.5 billion acquisition of Blueprint Medicines, its ongoing investment in Dupixent and the broader dupilumab franchise, and its AI and digital transformation initiatives. The Cheplapharm equity stake also means Sanofi retains financial participation in the mature medicines' future value rather than simply exiting them for cash.

The Connecting Themes

Three ideas connect every story published today. First, Novo's simultaneous rebrand, Anthropic collaboration, and macrocycle partnership reveal a company making concentrated bets across consumer brand positioning, AI infrastructure, and next-generation oral drug design simultaneously — a degree of strategic coordination that will define whether the new chapter Doustdar is launching actually delivers. Second, the precision immunology and T-cell engager wave continues — GSK's Chimagen deal joins the Simcere/Roche SIM0660 and Antengene/UCB ATG-201 transactions as evidence that multi-specific antibody technology from specialized biotechs is now the dominant deal category in oncology and autoimmune medicine. Third, large pharma's portfolio simplification is accelerating — Sanofi's Cheplapharm deal, like Novo's earlier decision to partner mature diabetes assets in Asia, reflects a clear industry consensus that the companies that will win the next decade are the ones that concentrate most aggressively on their highest-value innovation programs.